RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC)
To assess the efficacy and safety of RAD001 (everolimus) in non-clear cell renal cell carcinoma
Renal Cell Carcinoma
DRUG: RAD001
Progression-free survival, It is the time from treatment initiation until disease progression., 2 months, 4 months, 6 months
Response rate, It is the percentage of patients whose cancer shrinks or disappears after treatment., 2 months, 4 months, 6 months|Disease-control rate, It is the percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response and stable disease to a therapeutic intervention., 2 months, 4 months, 6 months|Overall survival, The length of time from either the date of diagnosis or the start of treatment for a disease that patients diagnosed with the disease are still alive., 2 months, 4 months, 6 months|Metabolic response rate by FDG-PET, It is assesed target lesions and non- target lesions by FDG-PET., 2 months, 4 months, 6 months|Safety, monthly
To assess the efficacy and safety of RAD001 (everolimus) in non-clear cell renal cell carcinoma